October 24, 2026 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Jade101 Administered Subcutaneously in Participants with IgAN Poster Presentation JADE101 American Society of Nephrology Kidney Week 2026
October 24, 2026 A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of JADE101 in Participants with Immunoglobulin A Nephropathy Poster Presentation JADE101 American Society of Nephrology Kidney Week 2026
October 22, 2026 Model-Based Assessment of Clinical Responses to APRIL Blockade Informing Development of the anti-APRIL mAb JADE101 in IgAN Poster Presentation JADE101 American Society of Nephrology Kidney Week 2026
September 30, 2026 Characterization and Development of JADE301, a Half-Life Extended Anti-IFN-β Monoclonal Antibody for Treatment of Dermatomyositis Poster Presentation JADE301 European Academy of Dermatology and Venereology Congress 2026
June 5, 2026 Interim Results of a Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JADE101 in Healthy Volunteers Poster Presentation JADE101 European Renal Association 2026 Congress
June 4, 2026 A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of JADE101 in Participants with IgAN Poster Presentation JADE101 European Renal Association 2026 Congress
November 8, 2025 Nonclinical Safety Profile of JADE101 Poster Presentation JADE101 American Society of Nephrology Kidney Week 2025
November 8, 2025 Translational Framework to Predict Clinical Responses to APRIL Blockade for Development of JADE101 Poster Presentation JADE101 American Society of Nephrology Kidney Week 2025
June 6, 2025 Discovery and Characterization of JADE101 Poster Presentation JADE101 European Renal Association 2025 Congress
